Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-PreEvent olpasiran cardiovascular outcomes trial
NL-OMON60782Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Sep 2025
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Olpasiran with Placebo (2 arms). Primary endpoint: Time to first occurrence of CHD death, myocardial infarction, or urgent coronary revascularization. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
olpasiran
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON60782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60782.